Video Player is loading.
Current Time 0:00
Duration 1:34:38
Loaded: 0.04%
Stream Type LIVE
Remaining Time 1:34:38
 
1x

미디어 오류

미디어를 로드하는 동안 오류가 발생했습니다. 나중에 다시 시도 해주십시오.

다시 시도하십시오

myPOCacademy에 가입하세요. 무료
과정은 CPD 인증입니다.

JOIN

프레젠테이션

  • Prof. Oliver Schnell

    Prof. Oliver Schnell
    (Germany)
    Chair

    Welcome and introductions

    English

  • Prof. Bernd Schultes

    Prof. Bernd Schultes
    (Switzerland)
    Speaker

    Insights from a Swiss competence centre for diabetology

    English

  • Dr Devaki Nair

    Dr Devaki Nair
    (UK)
    Speaker

    COVID-19 and diabetes in the UK – screening and monitoring

    English

  • Dr Peter Johansson

    Dr Peter Johansson
    (Sweden)
    Speaker

    Implementing a one stop shop for diabetes check-ups in a health care setting in Sweden

    English

  • Dr Enrico Torre

    Dr Enrico Torre
    (Italy)
    Speaker

    Perspective from Italy on Diabetes patients testing before and during the COVID-19 pandemic

    English

    Italian

  • Prof. Neale Cohen

    Prof. Neale Cohen
    (Australia)
    Speaker

    Alternative ways to manage diabetes patients during COVID-19. The point of care testing drive through experience

    English

  • Dr Erna Lenters-Westra

    Dr Erna Lenters-Westra
    (The Netherlands)
    Speaker

    Can high accuracy be achieved with point-of-care testing?

    English


제시된 견해와 의견은 저자의 것입니다. 이 웹캐스트에 포함된 콘텐츠는 정보 제공/교육 목적으로만 사용됩니다.

<strong>myPOCacademy</strong>에 가입하세요. <strong>무료</strong><br>과정은 <strong>CPD 인증</strong>입니다.

JOIN

Background

Join our panel of experts from around the world for this compelling event presenting a view from the front line on the management of diabetes patients and comorbidities in the context of COVID-19.

With telehealth and remote treatment on the rise, a unique and international group of experts will analyse how rapid point-of-care testing may benefit patients with diabetes in the COVID-19 healthcare landscape and beyond.

Screening and monitoring of diabetes and cardiovascular patients is even more critical nowadays. According to the World Health Organisation, individuals may be more susceptible to severe COVID-19 and death if they have a noncommunicable disease, such as diabetes, high blood pressure, cardiac disease, kidney disease, chronic lung disease, cerebrovascular disease or cancer. [1] Diabetes has not yet been shown to increase the likelihood of SARS-CoV-2 infection, but progression to severe illness is more likely in people with diabetes.2 The frequency of diabetes among COVID-19 patients requiring hospitalisation or intensive care is two to three times higher than in the overall population, and mortality rates in those with diabetes are also higher. [2] [3] [4] [5] [6] [7] [8].

Point-of-care testing for HbA1c aids in achieving improved glycaemic control with just one office visit. [9] [10] [11] [12]

In this educational event, the group of experts will share new strategies for the management of diabetes and comorbidities and how countries around the world are successfully adopting rapid HbA1c and lipid pointof-care testing for the continued remote management of diabetes and cardiovascular patients during COVID-19 and beyond.


제시된 견해와 의견은 저자의 것입니다. 이 웹캐스트에 포함된 콘텐츠는 정보 제공/교육 목적으로만 사용됩니다.

  1. World Health Organisation. Clinical management of COVID-19: Interim guidance, 27 May 2020. WHO/2019-nCoV/clinical/2020.5.
  2. Riddle M, Buse JB, Franks PW, et al. COVID-19 in People With Diabetes: Urgently needed Lessons From Early Reports. Diabetes Care. Published online May 14, 2020.
  3. Centers for Disease Control and Prevention. COVID-19 Response Team. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020. Morbidity and Mortality Weekly Report. April 3, 2020;69(13):382-386. https://www.cdc.gov/mmwr/volumes/69/wr/mm6913e2.htm
  4. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalised With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052-2059.
  5. Bode B, Garrett V, Messler J, et al. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalised in the United States. J Diabetes Sci Technol. Published online May 9, 2020.
  6. Palmieri L, Andrianou X, Barbariol P, et al. COVID-19 Surveillance Group. Characteristics of SARS-CoV-2 patients dying in Italy. Report based on available data on April 20, 2020. EpiCentro. Accessed June 5, 2020. https://www.epicentro.iss.it/en/coronavirus/ bollettino/Report-COVID-2019_20_April_2020.pdf
  7. Chen Y, Yang D, Cheng B. Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose Lowering Medication. Diabetes Care. Published online May 14, 2020.
  8. Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New Engl J Med. 2020;382:1708-20.
  9. Lian J, Liang Y. Curr Med Res & Op. 2014;30(11):2233-2240.
  10. Egbunike V, Gerard S. Diabetes Educator. 2013;39(1):66-73.
  11. Lee-Lewandrowski L, Yeh S, Baron J, Crocker JB, Lewandrowski K. Clin Chim Acta. 2017;473:71-74.
  12. Crocker JB, Lee-Lewandrowski E, Lewandrowski N, Baron J, Gregory K, Lewandrowski K. AJCP. 2014;142:640-646

<strong>&copy; 2022 Abbott. All rights reserved.</strong> All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. Any photos displayed are for illustrative purposes only. Any person depicted in such photos is a model. Products available in select markets only. COL-00000

<strong>myPOCacademy</strong>에 가입하세요. <strong>무료</strong><br>과정은 <strong>CPD 인증</strong>입니다.

JOIN